semaglutide savings Offer Program for patients taking Wegovy (semaglutide) injection 2.4 mg Ozempic Patient Assistance Program (PAP)
Description
The commercial potential will initially be driven by expansion in the private market, at least while public reimbursement remains constrained
As of May 2023, Ozempic and Wegovy are both listed on the FDAs Drug Shortages list, and as a result, Houston-based Empower Pharmacy began offering compounded GLP ones
They go through relatively small clinical trials, and then theyre released into the real world, where millions of people take them in ways they were never studied
Most people won't need to be on Wegovy for life to maintain weight loss
High treatment costs remain the biggest barrier to employer coverage of GLP-1 medications.
